beta-resorcylic acid has been researched along with ubiquinone 9 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acuña-Castroviejo, D; Barca, E; Cobos, EJ; Díaz-Casado, E; Escames, G; López, LC; Luna-Sánchez, M; Montilla-García, Á; Quinzii, CM; Tejada, MÁ | 1 |
| Acuña-Castroviejo, D; Bakkali, M; Barriocanal-Casado, E; Díaz-Casado, ME; Duarte, J; Escames, G; Hidalgo-Gutiérrez, A; López, LC; Prehn, C; Romero, M; Sánchez-Maldonado, L; Sayed, RK | 1 |
2 other study(ies) available for beta-resorcylic acid and ubiquinone 9
| Article | Year |
|---|---|
The clinical heterogeneity of coenzyme Q10 deficiency results from genotypic differences in the Coq9 gene.
Topics: Animals; Ataxia; Disease Models, Animal; Genetic Variation; Genotype; Hydroxybenzoates; Mammals; Mice; Mice, Transgenic; Mitochondrial Diseases; Muscle Weakness; Mutation, Missense; Ubiquinone | 2015 |
β-RA reduces DMQ/CoQ ratio and rescues the encephalopathic phenotype in
Topics: Animals; Brain; Disease Models, Animal; Energy Metabolism; Histocytochemistry; Hydroxybenzoates; Mice; Mitochondrial Encephalomyopathies; Neuroprotective Agents; Salicylic Acid; Survival Analysis; Treatment Outcome; Ubiquinone | 2019 |